ViAqua Therapeutics

Oral Delivery Platform for Preventing Aquaculture Diseases

Agriculture & Food Technologies
Private

Company Overview

Snapshot

Founded in September 2014 by Shai Ufaz and Shai Einbinder, ViAqua Therapeutics operates with 11–50 employees. The company has raised $16.05 million across 5 funding rounds from 11 investors. In September 2023, ViAqua Therapeutics secured funding, with.

Business overview

ViAqua Therapeutics develops an orally administered treatment platform aimed at improving health management and preventing viral epidemics within the aquaculture industry. The company's core technology utilizes a proprietary RNAi formulation delivered via coated particles in feed, designed to trigger the immune system and prevent viral infections in shellfish and fish. Its initial product targets shrimp, a significant segment of the international fish products trade, operating within the Agriculture & Food Technologies sector.

Strategic signal

In September 2023, ViAqua Therapeutics successfully raised an $8.25 million funding round. This capital infusion, which included participation from S2G Investments, signals strong investor confidence in the company's RNA-based aquaculture health platform and its potential to address critical disease challenges in the global seafood industry. The funding is expected to accelerate the development and commercialization of its oral delivery solutions for preventing viral epidemics in aquaculture.

Company Intelligence Q&A

What is ViAqua Therapeutics' primary focus?
ViAqua Therapeutics focuses on developing an orally administered treatment platform to enhance health management and prevent viral epidemics in aquaculture, particularly targeting shrimp initially.
When did ViAqua Therapeutics last raise funding?
In September 2023, ViAqua Therapeutics raised $8.25 million in a funding round, with.
What technology does ViAqua Therapeutics utilize?
ViAqua Therapeutics employs a proprietary RNAi formulation delivered through coated particles via feed. This technology is designed to trigger the immune system and prevent viral infections in aquatic species.
Which investors participated in the June 2021 funding round?
In June 2021, ViAqua Therapeutics received funding from investors including.
What was a notable early investment in ViAqua Therapeutics?
In July 2018, Dutch animal feed company Nutreco invested in ViAqua Therapeutics, highlighting early strategic interest in the company's medical aquafarming technology.

External links